Iovance Biotherapeutics expands pipeline of TIL therapies into lung cancer
Iovance Biotherapeutics announced that patient enrollment has begun in a study combining TIL and nivolumab in advanced non-small cell lung cancer patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute, Stand Up to Cancer and other partners. December 13, 2017